We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 28 Sep 2021

Randox Laboratories (Crumlin, UK) showcased its pioneering diagnostic technologies at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, which saw breakthrough innovations shaping the future of clinical testing and patient care. More...

With more than 400 companies exhibiting, the 2021 AACC Clinical Lab Expo is the premier global laboratory medicine exposition. Among its diverse product range displayed at AACC 2021 were third party quality control solutions, diagnostic reagents which included many niche & superior performance assays, clinical chemistry analyzers, molecular diagnostic solutions for infectious diseases including COVID-19 and patented biochip technology. The revolutionary biochip is capable of simultaneously detecting hundreds of targets from a single patient sample. Complete patient profiling in this way facilitates faster patient testing, earlier diagnosis and improved patient pathways.

Randox also demonstrated its Qnostics range of molecular controls for infectious diseases comprising hundreds of characterized viral, bacterial and fungal targets covering a wide range of diseases and infections. Comprising hundreds of characterized viral, bacterial and fungal targets, the Qnostics range includes transplant associated diseases, respiratory diseases, blood borne viruses, sexually transmitted infections, gastrointestinal infections and central nervous system diseases. The products can be used in the daily monitoring of assay performance, linearity assessment, assay evaluation, validation and verification of new assays and staff training.

Also on display at the event were the company’s Acusera Anti-SARS-CoV-2 controls which support assay validation and routine performance monitoring of serological assays for COVID-19. Conveniently supplied in a liquid format, this control has unrivalled 30-day open vial stability, therefore keeping waste to a minimum.

Related Links:
Randox Laboratories


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researcher Joris Deelen (Photo courtesy of Elton Alisson/Agência FAPESP)

Blood-Based Score May Support Targeted Interventions for Healthier Aging

Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test Identifies Early Breast and Prostate Cancer Signals Years Before Diagnosis

Breast and prostate cancers are among the most common cancers, yet many are detected only after tumors have become established. Identifying disease earlier could support closer monitoring and help distinguish... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.